StreetInsider.com News Articles

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Fri, 23 Oct 2026 20:00:00 -0400

ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight’s common stock to two new non-executive officer employees in connection with the commencement of their employment with RxSight. RxSight also agreed to grant inducement restricted stock units (RSUs) covering a total of 637,449 shares of RxSight’s common stock to the same employees in connection with the commencement of their employment with RxSight, which RSUs are anticipated to be granted on or about November

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Fri, 23 Oct 2026 20:00:00 -0400

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

Tue, 20 Oct 2026 16:05:00 -0400

ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 8782462. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

Tue, 20 Oct 2026 16:05:00 -0400

RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation

Mon, 19 Oct 2026 09:00:00 -0400

ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy. The appointments strengthen RxSight’s commercial leadership team and support the company’s efforts to enhance commercial execution and accelerate adoption of RxSight’s Light Adjustable Lens™ (LAL™) technology.

“Over the past several months, we have prioritized investment to strengthen our commercial organization, and the appointments of Taryn and Frank are another important step in that process,” said Aziz Mottiwala, President and Chief Executive

RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation

Mon, 19 Oct 2026 09:00:00 -0400

Form 4 RxSight, Inc. For: Sep 15 Filed by: Weinberg Eric

Wed, 16 Sep 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260916/27070585.html

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

Wed, 26 Aug 2026 16:15:00 -0400

ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company’s investor relations website at https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight^® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens^® (LAL^®/LAL+^®,

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

Wed, 26 Aug 2026 16:15:00 -0400

About RxSight, Inc.

Form SC TO-I/A RxSight, Inc. Filed by: RxSight, Inc.

Tue, 25 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26970282.html

Form SC TO-I/A RxSight, Inc. Filed by: RxSight, Inc.

Tue, 25 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26970282.html

Form SCHEDULE 13G RxSight, Inc. Filed by: Point72 Asset Management, L.P.

Wed, 19 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260819/26950143.html

Form SCHEDULE 13G RxSight, Inc. Filed by: Point72 Asset Management, L.P.

Wed, 19 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260819/26950143.html

Form 144 RxSight, Inc. Filed by: COHEN RAYMOND W

Tue, 18 Aug 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260818/26945657.html

Form 144 RxSight, Inc. Filed by: COHEN RAYMOND W

Tue, 18 Aug 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260818/26945657.html

Form SC TO-I RxSight, Inc. Filed by: RxSight, Inc.

Mon, 10 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260810/26894755.html

Form SC TO-I RxSight, Inc. Filed by: RxSight, Inc.

Mon, 10 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260810/26894755.html

RxSight Inc. (RXST) PT Lowered to $7 at Stifel Amid U.S. Adoption Challenges

Mon, 10 Aug 2026 07:47:48 -0400

Stifel analyst Tom Stephan lowered the price target on RxSight Inc. (NASDAQ: RXST) to $7.00 (from $8.00) while maintaining a Hold rating.

The analyst commented, "Recall, RXST pre-announced weak 2Q26 results in July alongside its ALC collaboration announcement. We now update our model following the 2Q26 10-Q and earnings release, where the only meaningful incremental development was withdrawal of guidance. This seemingly is not a reflection of worsening trends (which have improved quarter-to-date)—rather, new CEO Aziz Mottiwala appears intent on not allowing prior guidance to constrain decision-making. We came away encouraged by our initial interaction with Mr. Mottiwala, whose ophthalmology experience—most

RxSight Inc. (RXST) PT Lowered to $7 at Stifel Amid U.S. Adoption Challenges

Mon, 10 Aug 2026 07:47:48 -0400

Stifel analyst Tom Stephan lowered the price target on RxSight Inc. (NASDAQ: RXST) to $7.00 (from $8.00) while maintaining a Hold rating.

RxSight, Inc. (RXST) Tops Q2 EPS by 25c

Wed, 05 Aug 2026 16:32:24 -0400

RxSight, Inc. (NASDAQ: RXST) reported Q2 EPS of ($0.11), $0.25 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $33.74 million versus the consensus estimate of $32.21 million.

For earnings history and earnings-related data on RxSight, Inc. (RXST) click here.

Form 10-Q RxSight, Inc. For: Jun 30

Wed, 05 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26874591.html

Form 10-Q RxSight, Inc. For: Jun 30

Wed, 05 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26874591.html

Form 8-K RxSight, Inc. For: Aug 05

Wed, 05 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260805/26874538.html

Form 8-K RxSight, Inc. For: Aug 05

Wed, 05 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260805/26874538.html

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

Wed, 05 Aug 2026 16:05:00 -0400

ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook.

Second Quarter 2026 Highlights

Total company Q2 revenue of $33.7 million, which includes $6.5 million in revenue recognized from the RxSight Alcon strategic collaboration
Q2 product sales of $27.2 million including:
- 24,917 Light Adjustable Lens (LAL) units;
- 12 Light Delivery Devices (LDD) units
Cash, cash equivalents and short-term investments of approximately $209 million as of June 30, 2026